C. W. Vander Kooi

This study investigates the role of TgLaforin, a glucan phosphatase, in Toxoplasma gondii by showing its impact on glucan metabolism, virulence, and bradyzoite survival during chronic infection.

This paper develops an empirical pipeline to classify EPM2A mutations in Lafora disease by analyzing their functional impact in vitro, linking specific mutations to clinical outcomes.

This study generates and characterizes laforin nanobodies to inhibit its catalytic activity and better understand its role in Lafora disease.

This study evaluates the cerebral delivery and biodistribution of VAL-0417, an antibody-enzyme fusion for Lafora disease, showing intracerebroventricular administration is most effective.